- • Ideal formats for identifying and quantifying NAb response
- • Improvement of drug tolerance in ADA assays transitioning between phases of drug development
- • Broadening the types and useful applications of humanized mouse models
- • Worldwide experience of immunogenicity assessment of biosimilars
- • Clinical use of nanoparticles to avoid immunogenicity
- • Evaluating immunogenicity of multi-domain vs. typical biotherapeutics
- • Optimization of the performance of monoclonal antibodies in-vivo
For more information on the entire Immunogenicity program, download the brochure.
The Immunogenicity for Biotherapeutics Conference is taking place March 18-20, 2013, in Baltimore, MD. Reader of this blog, you receive an exclusive discount of 15% off the standard rate when you register using code XP1838BLOG. If you have any questions about the agenda, feel free to contact Jennifer Pereira.
Share this article with your social network, just click below to share now!
|
|
No comments :
Post a Comment